On April 24, NeuroMax, Ltd., a portfolio company of Maxwell Biotech Venture Fund, founded with the participation of RVC, received an authorization by the Ministry of Healthcare and Social Development of the Russian Federation to carry out clinical trials of...
NeuroMax has successfully completed Phase Ia clinical trials on the safety and pharmacokinetics of drug candidate NM-IA-001 (BNV-222) for patients with diabetic neuropathy. Previously approved by the Ministry of Health of the Russian Federation the study was...
NeuroMax has received permission from the Ministry of Health of the Russian Federation to conduct Phase Ib clinical trial to study the safety and pharmacokinetics of developed drug candidate NM-IA-001 (BNV-222, choline diepalrestat) in patients with diabetic...
Maxwell Biotech Venture Fund created with the participation of RVC is increasing assets in accordance with its development strategy. NeuroMax, Ltd was founded in 2010 in order to develop and market innovative drugs for treatment of CNS and PNS diseases. The...
NeuroMax, Ltd a Russian private biotech company, financed by Maxwell Biotech Venture Fund, which was set up with the participation of RVC, has announced the launch of Phase Ib clinical trial of its pharmaceuticals NM-IA-001 (BNV-222), intended for the pathogenetic...